Bathla Group Hires Administrators as Australia Housing Slump Deepens 
SK Hynix Shares Fall as Workers Reject Wage Deal 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Trump Buys SpaceX Shares After Record IPO 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Add as a preferred source on Google
CAMBRIDGE, Mass., May 01, 2018 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 1:30 PM ET in Boston, MA.
A live webcast of the presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
Investor and Media Contact:
Komal Joshi
Jounce Therapeutics, Inc.
(857) 320-2523
[email protected]
